The Effect of Cannabis in Pancreatic Cancer
Launched by JENS RIKARDT ANDERSEN · Aug 9, 2017
Trial Information
Current as of May 22, 2025
Withdrawn
Keywords
ClinConnect Summary
Randomization of consecutive patients who wanted to participate to a daily dose of CBD or not as a supplement to the standard treatment.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adult, palliative pancreatic cancer diagnosis, weight loss \> 5%, understand and read Danish.
- Exclusion Criteria:
- • Regular use of cannabis, psychiatric disorders, alcohol abuse, life expectancy \< 6 months
About Jens Rikardt Andersen
Jens Rikardt Andersen is a dedicated clinical trial sponsor with a focus on advancing medical research and innovation. With a commitment to improving patient outcomes, the organization collaborates with healthcare professionals and institutions to design and implement rigorous clinical studies. By prioritizing ethical standards and regulatory compliance, Jens Rikardt Andersen ensures the integrity of data collection and analysis, fostering a robust environment for the development of new therapies and interventions. Their expertise extends across various therapeutic areas, positioning them as a key player in the clinical research landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Naestved, , Denmark
Patients applied
Trial Officials
Jens Rikardt Andersen, MD, MPA
Principal Investigator
University of Copenhagen
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials